Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Practice-Changing Data in NSCLC from ASCO 2021

Conference Correspondent  - AACR & ASCO 2021 - Midyear Review
Dr Mark Socinski provides his insights into important new data on EGFR inhibitors and immunotherapy in the first-line setting for NSCLC.
Related Items
2021 Midyear Review: Non–Small-Cell Lung Cancer
Conference Correspondent  published on June 20, 2021 in AACR & ASCO 2021 - Midyear Review
Combination Therapies and New Molecular Targets—Presentations from AACR 2021
David Spigel, MD
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Acquired Resistance Mutations After Treatment of EGFR-Mutated Metastatic NSCLC with Osimertinib plus Savolitinib (TATTON)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of Osimertinib + Oleclumab in Progressive T790M-Negative EGFR-Mutated NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of D-0316 in Patients with Advanced NSCLC and EGFR T790M Mutation
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.